ProSomnus Sleep Technologies has received U.S. Food and Drug Administration Class II 510(k) clearance for its RPMO₂ OSA Device, a novel theragnostic tool that could disrupt the multi-billion dollar sleep apnea market. The clearance, granted on April 13, 2026, paves the way for the first device to combine precision oral appliance therapy and multi-night physiologic monitoring.
"This is a pivotal moment for sleep medicine and the millions of patients who struggle with OSA," said John E. Jones, CEO of ProSomnus. "The RPMO₂ device is a testament to our commitment to pioneering Smart Sleep Medicine, offering a patient-friendly, non-CPAP alternative that provides clinicians with the data they need to deliver personalized and effective care."
The clearance (K252765) covers five product codes (DQA, LQZ, LRK, PLC, and OUG), designating the RPMO₂ as a Class II medical device. Unlike traditional CPAP machines, which are often criticized for their bulkiness and low compliance rates, the ProSomnus device is a precision oral appliance. Its integrated monitoring capabilities allow for the continuous tracking of treatment efficacy over multiple nights, a feature not previously available in a single device.
For investors, the FDA clearance is a significant de-risking event that validates ProSomnus's technology and opens the door to the vast U.S. market for OSA treatment. The company now has a clear path to compete with established players like ResMed and Philips in the non-CPAP segment. This could translate to substantial revenue growth and an increase in the company's stock price as it captures a share of the estimated 29.4 million adults in the U.S. with sleep apnea.
The RPMO₂ device's "theragnostic" nature—combining therapy and diagnostics—is its key innovation. Traditional oral appliances are often a "set and forget" therapy, with limited ways to track their effectiveness without follow-up sleep studies. ProSomnus's device aims to solve this by embedding physiologic sensors that can monitor key metrics, providing both patients and doctors with objective data on treatment progress. This data-driven approach is expected to improve patient outcomes and adherence.
The clearance is also a major competitive differentiator. While other companies offer oral appliances, none currently have an integrated multi-night monitoring system cleared by the FDA. This positions ProSomnus as a leader in the emerging field of "Smart Sleep Medicine," potentially attracting partnerships with other healthcare technology companies and insurers who are keen on data-backed, value-based care models. The company's stock, which has been watched closely by analysts, is expected to react positively to the news.
This article is for informational purposes only and does not constitute investment advice.
